J. Safra Sarasin Holding AG Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

J. Safra Sarasin Holding AG lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 80,972 shares of the company’s stock after selling 12,497 shares during the quarter. Eli Lilly and Company comprises about 1.1% of J. Safra Sarasin Holding AG’s holdings, making the stock its 29th largest position. J. Safra Sarasin Holding AG’s holdings in Eli Lilly and Company were worth $62,510,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its stake in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the period. Invst LLC raised its position in Eli Lilly and Company by 3.5% in the third quarter. Invst LLC now owns 5,552 shares of the company’s stock valued at $4,918,000 after purchasing an additional 189 shares during the period. McIlrath & Eck LLC lifted its stake in Eli Lilly and Company by 3.4% during the third quarter. McIlrath & Eck LLC now owns 481 shares of the company’s stock worth $426,000 after purchasing an additional 16 shares in the last quarter. Virtu Financial LLC boosted its position in shares of Eli Lilly and Company by 111.7% during the third quarter. Virtu Financial LLC now owns 6,531 shares of the company’s stock worth $5,786,000 after buying an additional 3,446 shares during the period. Finally, SOA Wealth Advisors LLC. grew its stake in shares of Eli Lilly and Company by 2.4% in the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company’s stock valued at $766,000 after buying an additional 20 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley decreased their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Citigroup lowered their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Finally, Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,012.00.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $841.70 on Monday. The company has a market capitalization of $798.08 billion, a price-to-earnings ratio of 71.88, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a 50 day moving average price of $829.09 and a 200 day moving average price of $819.40.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.